Psychedelic and ketamine research trials in Sweden
Data as of 11 October 2026. Source: ClinicalTrials.gov records held by PsychoactiveMap, refreshed from a reviewed snapshot.
6 registered studies are counted in Sweden. By compound: 3 psilocybin and 3 ketamine. By registry status: 2 recruiting, 1 not yet recruiting, 1 active, not recruiting and 2 completed. By phase: 5 phase 2 and 1 not applicable. Reported start years run from 2015 (earliest) to 2026 (latest). Studies are linked to 4 institutions.
Country is taken from the research site linked to each registry record. A study counts once, and a study tagged with more than one compound is counted under each compound. Ketamine studies are counted only when PsychoactiveMap classifies them as psychiatric research; anaesthesia, sedation and pain studies are left out.
Educational information, not medical advice. A registry listing is not evidence of safety, benefit or results, and it is not a recommendation. PsychoactiveMap does not recruit, screen or refer participants. Status and other details are copied from the registry and can be out of date, so check the registry record and speak to a qualified health professional before any decision. Read the full disclaimer.
Recruiting now
3 of the 6 counted studies are listed in the registry as recruiting (2) or not yet recruiting (1), newest start first. Status is reported by study teams and can be out of date. PsychoactiveMap does not recruit, screen or refer anyone; eligibility and contact details are on each registry record.
| Title as registered | Registry ID | Status | Phase | Start | Institution and city |
|---|---|---|---|---|---|
| Ketamine Treatment for Treatment-Resistant Depression - the Role of Framing | NCT07824973 | Not yet recruiting | Not applicable | 2026-09-01 | Vastra Gotaland Region, Skövde |
| Safety, Therapeutic Potential, and Mechanisms of Two Psilocybin Doses, Administered With Psychological Support in Young Adults With Anorexia Nervosa | NCT07169747 | Recruiting | Phase 2 | 2025-10-01 | Region Skane, Lund |
| Cancer Related Major Depression Treated With a Single Dose of Psilocybin | NCT06319378 | Recruiting | Phase 2 | 2024-04-17 | Section for Affective Disorders; Northern Stockholm Psychiatry, Gothenburg |
At a glance
- 6 registered studies are counted on this page.
By compound
| Compound hub | Studies |
|---|---|
| Psilocybin | 3 |
| Ketamine | 3 |
By registry status
| Status | Studies | Share |
|---|---|---|
| Recruiting | 2 | 33% |
| Not yet recruiting | 1 | 17% |
| Active, not recruiting | 1 | 17% |
| Completed | 2 | 33% |
By phase
| Phase | Studies | Share |
|---|---|---|
| Phase 2 | 5 | 83% |
| Not applicable | 1 | 17% |
When studies started
| Start year | Studies |
|---|---|
| 2024 to 2026 | 4 |
| 2020 to 2023 | 1 |
| 2015 to 2019 | 1 |
All counted studies
All 6 counted studies, newest start first. The order is not a ranking and says nothing about quality. Titles are quoted from the registry. Each ID links to its own ClinicalTrials.gov record, which has the eligibility criteria and contacts.
| Title as registered | Registry ID | Status | Phase | Start | Institution and city |
|---|---|---|---|---|---|
| Ketamine Treatment for Treatment-Resistant Depression - the Role of Framing | NCT07824973 | Not yet recruiting | Not applicable | 2026-09-01 | Vastra Gotaland Region, Skövde |
| A Clinical Trial of Add-on Oral Slow-release Ketamine Treatment in Major Depression | NCT07396272 | Active, not recruiting | Phase 2 | 2026-03-01 | Region Skane, Lund |
| Safety, Therapeutic Potential, and Mechanisms of Two Psilocybin Doses, Administered With Psychological Support in Young Adults With Anorexia Nervosa | NCT07169747 | Recruiting | Phase 2 | 2025-10-01 | Region Skane, Lund |
| Cancer Related Major Depression Treated With a Single Dose of Psilocybin | NCT06319378 | Recruiting | Phase 2 | 2024-04-17 | Section for Affective Disorders; Northern Stockholm Psychiatry, Gothenburg |
| The Effect of Psilocybin on MDD Symptom Severity and Synaptic Density | NCT04630964 | Completed | Phase 2 | 2021-01-01 | Section for Affective Disorders; Northern Stockholm Psychiatry, Stockholm |
| Ketamine as an Alternative Treatment to ECT in Major Depressive Disorder | NCT02659085 | Completed | Phase 2 | 2015-02-01 | Region Skane, Lund |
About this data
Compound tags come from automated matching of the registry search term and have not been checked record by record. Counts are of registered studies, not of people, results or approvals. A registry listing is not evidence of safety, benefit or results.
Substance hubs for these compounds
Institution hubs in this country
Institutions in this country with at least 3 counted studies. The number is that institution's own count of studies, which can include studies not shown above if the registry lists them under another country.
- Region Skane: 3 studies
Condition hubs
Condition hubs that include studies counted in this country, with the number of those studies. Conditions are matched by keyword on registered titles, so one study can appear under more than one condition.
| Condition hub | Studies in this country |
|---|---|
| Depression | 5 |
| Cancer and end-of-life distress | 1 |
| Eating disorders | 1 |
| Treatment-resistant depression | 1 |
Other country hubs
United States | Canada | Switzerland | United Kingdom | France | Israel | Brazil | China | Netherlands | Australia | Austria | Germany | Spain | Argentina | Belgium | Egypt | Mexico | Poland | Taiwan | Ireland | Czech Republic | Denmark | Finland